Metindol retard, 75 mg 25 pcs

Methindol retard has anti-inflammatory, analgesic, antipyretic, desensitizing effect.

Blocks cyclooxygenase in arachidonic acid cascade, inhibits GH biosynthesis.

Indications

Use strictly as prescribed by your doctor!
The drug is intended for symptomatic treatment of inflammatory diseases accompanied by pain.
– ankylosing spondylitis (Bechterew’s disease) and other inflammatory-rheumatic diseases of the spine;
– gouty arthritis;
– rheumatoid arthritis;
– pain syndrome in diseases of the spine;
– rheumatic diseases of soft tissues;
– pain and inflammation after injuries and surgical interventions (gynecological, dental, etc.).

Pharmacological effect

Methindol retard has anti-inflammatory, analgesic and antipyretic effects. The mechanism of action of the drug is associated with inhibition of the activity of the cyclooxygenase enzyme and a decrease in the synthesis of prostaglandins, which cause pain, increased temperature and increased tissue permeability at the site of inflammation.
For articular syndrome, Methindol retard reduces inflammation and relieves pain at rest and during movement, reduces morning stiffness and swelling of the joints, and helps increase range of motion.

Special instructions

During treatment, it is necessary to monitor the peripheral blood picture and the functional state of the liver and kidneys.
If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study.
It is necessary to monitor liver function and the cellular composition of peripheral blood.
To prevent and reduce dyspeptic symptoms, antacid drugs should be used.
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Indomethacin

Composition

1 tablet contains:
active substance:
indomethacin 75.0 mg
excipients:
microcrystalline cellulose 48.6 mg; potato starch 16.2 mg; methacrylic acid copolymer 5.4 mg; talc 1.8 mg; magnesium stearate 3.0 mg.

Contraindications

– congenital heart defects (severe coarctation of the aorta, pulmonary atresia, severe tetralogy of Fallot), the drug is contraindicated in the period after coronary artery bypass grafting;
– blood clotting disorders (including hemophilia, prolongation of bleeding time, bleeding tendency);
– pregnancy, lactation period;
– known hypersensitivity to indomethacin and other components of the drug;
– history of bronchospasm, urticaria or rhinitis caused by taking acetylsalicylic acid or other NSAIDs (complete or incomplete acetylsalicylic acid intolerance syndrome – rhinosinusitis, urticaria, nasal polyps, asthma);
– erosive and ulcerative changes in the mucous membrane of the stomach and/or duodenum, active gastrointestinal bleeding;
– exacerbation of inflammatory bowel diseases (nonspecific ulcerative colitis, Crohn’s disease);
– severe liver failure or active liver disease;
– severe renal failure (creatinine clearance less than 30 ml/min), progressive kidney disease;
– confirmed hyperkalemia;
– children and youth (up to 18 years).

Side Effects

From the digestive system: NSAID gastropathy, abdominal pain, nausea, vomiting, heartburn, loss of appetite, diarrhea, impaired liver function (increased activity of “liver” transaminases, hyperbilirubinemia), ulceration of the gastrointestinal mucosa (including with perforation and/or bleeding).
From the nervous system: headache, dizziness, insomnia, agitation, irritability, excessive fatigue, drowsiness, depression, peripheral neuropathy.
From the senses: taste disturbance, hearing loss, tinnitus, diplopia, blurred vision, corneal clouding, conjunctivitis.
From the cardiovascular system: development (worsening) of chronic heart failure, tachyarrhythmia, edema syndrome, increased blood pressure.
From the urinary system: impaired renal function, proteinuria, hematuria, interstitial nephritis, nephrotic syndrome, papillary necrosis.
From the hematopoietic organs and hemostasis system: bleeding (gastrointestinal, gingival, uterine, hemorrhoidal), anemia (including hemolytic and aplastic), leukopenia, thrombocytopenia, eosinophilia, agranulocytosis, thrombocytopenic purpura.
Allergic reactions: skin rash, skin itching, urticaria, angioedema, bronchospasm; in isolated cases – photosensitivity, toxic epidermal necrolysis (Lyell’s syndrome), erythema nodosum, anaphylactic shock.
Laboratory indicators: agranulocytosis, leukopenia, thrombocytopenia, hyperglycemia, glycosuria, hyperkalemia.
Other: aseptic meningitis (more often in patients with autoimmune diseases), increased sweating, aplastic anemia, autoimmune hemolytic anemia.

Interaction

Increases plasma concentrations of digoxin, methotrexate and lithium preparations, which can lead to increased toxicity.
Ethanol, colchicine, corticosteroids and corticotropin increase the risk of gastrointestinal bleeding. Enhances the hypoglycemic effect of insulin and oral hypoglycemic drugs; enhances the effect of indirect anticoagulants, antiplatelet agents, thrombolytics (alteplase, streptokinase and urokinase) – there is a risk of bleeding.
Reduces the effect of diuretics; with the use of potassium-sparing diuretics, the risk of hyperkalemia increases; reduces the effectiveness of uricosuric and antihypertensive drugs (including beta-blockers); enhances the side effects of glucocorticosteroids, acetylsalicylic acid, estrogens, and other NSAIDs.
Cyclosporine and gold preparations increase nephrotoxicity (apparently by suppressing the synthesis of prostaglandins in the kidneys).
Cefamandole, cefaperazone, cefotetan, valproic acid, plicamycin increase the incidence of hypoprothrombinemia and the risk of bleeding. Antacids and cholestyramine reduce the absorption of indomethacin.
Increases the toxicity of zidovudine (due to inhibition of metabolism); in newborns, it increases the risk of developing toxic effects of aminoglycosides (since it reduces renal clearance and increases blood concentrations).
Concomitant use with serotonin reuptake inhibitors increases the risk of gastrointestinal bleeding.
Myelotoxic drugs enhance the manifestations of hematotoxicity of the drug. Concomitant use with paracetamol increases the risk of nephrotoxic effects.

Overdose

Symptoms:
The clinical picture of an overdose with Methindol retard is characteristic of indomethacin and includes the following symptoms: nausea, vomiting, severe headache, dizziness, memory impairment and disorientation. In more severe cases, paresthesia, numbness of the limbs and convulsions are observed.
Treatment:
Treatment consists of quickly removing the drug from the body and using appropriate symptomatic remedies. Indomethacin cannot be removed from the body by hemodialysis.

Storage conditions

Store in original packaging at a temperature not exceeding 25 °C.
Keep out of the reach of children!

Shelf life

5 years.
Do not use after the expiration date indicated on the package.

Manufacturer

ICN Polfa Rzeszow AD, Poland